Detail akcie Danaher Corp online

Business Summary: Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three business segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a range of instruments, consumables, services and software that are primarily used by customers to study genomics and the basic building blocks of life, including deoxyribonucleic acid (DNA)and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
Financial Summary: BRIEF: For the three months ended 29 March 2024, Danaher Corp revenues decreased 3% to $5.8B. Net income applicable to common stockholders excluding extraordinary items decreased 11% to $1.09B. Revenues reflect Biotechnology segment decrease of 18% to $1.52B. Net income also reflects Biotechnology segment income decrease of 45% to $325M, Life Sciences segment income decrease of 27% to $235M, Other segment loss increase of 1% to $78M.